Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures

NCT: NCT04796350 · RECRUITING

NCT IDNCT04796350
StatusRECRUITING
Start Date2021-04-24
Completion2029-04-01
SponsorAgNovos Healthcare, LLC (INDUSTRY)
First posted
Last updated

Brief Summary

A randomized controlled trial to evaluate AGN1 to prevent secondary hip fractures in osteoporotic women undergoing treatment of index hip fractures. Up to 2400 subjects will be randomized between a treatment group and a control group. Subjects will be followed for a minimum of 5 years after undergoing hip fracture repair surgery.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑